How do GLP-1 and GIP differ?
GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide) are two distinct incretin hormones secreted by different intestinal cell populations and engaging different receptors, both with insulin-secretion effects but distinct broader pharmacology.
What the research literature says
GLP-1 is a 30-31 amino-acid peptide secreted by intestinal L-cells in the distal small intestine and colon in response to nutrient intake. It engages the GLP-1 receptor on pancreatic beta cells, gastric tissue, and central nervous system regions involved in appetite regulation. Beyond insulin secretion, GLP-1 produces glucagon suppression, slowed gastric emptying, and centrally-mediated satiety effects.
GIP is a 42 amino-acid peptide secreted by intestinal K-cells in the proximal small intestine in response to nutrient intake. It engages the GIP receptor on pancreatic beta cells (and on adipocytes and other tissues), producing glucose-dependent insulin secretion as its primary action. GIP’s role in appetite regulation is less central than GLP-1’s, and its effect on glucagon is more complex (GIP stimulates glucagon under low-glucose conditions while GLP-1 suppresses glucagon under high-glucose conditions).
The research-pharmaceutical convergence on both incretins has come through dual-receptor agonists — most notably tirzepatide, the dual GIP + GLP-1 agonist characterised in the Willard pharmacology work (PMID 32730231) and the SURPASS clinical-trial program (PMID 34170647). Single-receptor GLP-1 agonists like semaglutide represent the prior-generation approach (PMID 33567185). Triple-receptor extends the framework with glucagon-receptor agonism added (PMID 37366315).
Why this matters in research context
The GLP-1 vs GIP distinction is the central pharmacological axis in modern incretin-research. Researchers studying single-receptor vs multi-receptor pharmacology need to understand the differential mechanisms; researchers studying tirzepatide’s biased GIP-receptor agonism need to distinguish it from native GIP pharmacology. The published research literature on both incretins is extensive and dates back decades.
Related compounds
- Semaglutide 10mg — single-receptor GLP-1 agonist
- Tirzepatide 10mg — dual GIP + GLP-1 agonist
Related research questions
References
- Willard FS et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 2020;5(17):e140532. [PMID 32730231]
- Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385(6):503-515. [PMID 34170647]
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384(11):989-1002. [PMID 33567185]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.